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In a 5-year retrospective study, we used spoligotyping
and mycobacterial interspersed repetitive units to type 13
strains of Mycobacterium bovis isolated from human
sources. Despite the relatively high incidence of human
tuberculosis caused by M. bovis (2%), these tools showed
no clonal evolution and no relationships between the
isolates.
M
ycobacterium bovis belongs to the M. tuberculosis
complex (MTBC) and has a wide host range, infect-
ing animals and occasionally humans. M. bovis has been a
historical source of tuberculosis (TB) in humans infected
through drinking contaminated unpasteurized milk or
inhaling aerosols produced by diseased farm animals. Due
to a national program of TB control, the incidence of M.
bovis in France has dramatically decreased in cattle herds,
falling from 10% in the1960s to 0.09% in 1998, and in
humans, falling from 1.5% of TB cases in the 1960s to
0.5% (0.07/100,000) in 1995 (1,2). We describe 13 (2 were
BCG strains) of 555 MTBC strains isolated from human
samples (2% of incidence; we did not quantify the BCG
strains), in Lyon, France, over a period of 5 years. Despite
the small number of patients, our study shows a relatively
high local incidence of infections caused by M. bovis.
Advances in molecular typing have improved our under-
standing of the dissemination of M. bovis and helped
improve our ability to distinguish among strains.
Spoligotyping and mycobacterial interspersed repetitive
units–variable-number tandem repeats (MIRU-VNTR) are
now considered standard alternative molecular techniques
(3,4). Both are PCR-based techniques that evaluate the
polymorphism of the tandem repeat copy number at sever-
al loci and have been used to identify different strains of
M. bovis (5,6). We used these molecular methods to iden-
tify different strains of M. bovis.
The Study
From 2000 to 2005, positive cultures were obtained
from 13 patients with a diagnosis of M. bovis infection.
The strains were screened by using pncA gene for resist-
ance to pyrazinamide sequencing, and all displayed the
169 C→G mutation (7). To differentiate between M. bovis
and M. bovis BCG, we tested for the presence or absence
of the region of difference 1 because the absence of this
region is a specific marker of BCG strains (7,8).
Spoligotyping was performed in accordance with
Kamerbeek guidelines, and the data were compared with
the Institute Pasteur (IP) Spoligotype Database and with
the International M. bovis Spoligotype Database (9,10).
We performed MIRU-VNTR typing as described by
Supply et al. (11,12).
Patient age, sex, sample site, and country of birth are
provided in Table 1. Most of the clinical samples were
from lymph nodes (n = 6). Others samples were from urine
(n = 2), lung (n = 1), sputum (n = 1), cerebrospinal fluid (n
= 1), ascitic fluid (n = 1), and synovial fluid (n = 1). Patient
SO, who was 4 years old when his condition was diag-
nosed, had been born in France, but he spent months in
Algeria with his grandmother who was ill with TB. Patient
GD had a history of BCG-disseminated infection after
being vaccinated with a BCG strain when he was 1 year of
age. His condition had also been diagnosed as a familial
form of septic granulomatosis, and he was immunocom-
promised. The strain was isolated only after he underwent
lymph node resection at the age of 17. The bacillus isolat-
ed was an M. bovis BCG strain. Patient BL had undergone
immunotherapy with a BCG strain for bladder cancer, and
a BCG infection of the bladder developed.
The results of spoligotyping and MIRU are shown in
Table 2. Spoligotype profiles were typical of M. bovis with
the absence of spacers 3, 9, 16, and 39–43 (1,13). Four dis-
tinct patterns were identified; the main one corresponded
to spoligotype 482 in the IPdatabase (70% of strains); both
BCG strains exhibited this pattern. Others patterns repre-
sented were spoligotype 481 (2 strains) and 2 that were not
included in the IP database (although one was identified as
SB0914 in the international spoligotype database). These 2
spoligotypes (481 and 482) have been reported by Haddad
et al. as the ones most commonly seen in bovine TB in
France (1). Patient MB’s spoligotype was not found in the
databases, likely because of its origin (this patient was
born in Djibouti), and it could be native to Africa.
MIRU typing identified 12 individual patterns; 2 strains
possessed the same MIRU patterns but not the same
spoligotype. Both BCG strains showed the same pattern,
except at locus 4 (14). Patient BL was found to have a
BCG strain with 1 copy on locus 4. This profile is very
similar to that of the Connaught strain used for the treat-
ment of bladder cancer, which also has 1 copy at locus 4.
Patient GD’s strain of BCG had 2 copies at locus 4. This
characteristic is similar to that of the BCG strain used for
human vaccination in France (Mérieux strain derived from
the Glaxo 1077 strain) (14).
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This 5-year study of human M. bovis infections in
humans leads to 3 main conclusions. First, we observed a
relatively high incidence of this disease: 2% of TB cases
were caused by M. bovis, compared with 0.5% reported 10
years earlier and ≈1% reported in England by Smith in
2004 (15). Second, in France TB caused by MTBC occurs
mainly in patients born abroad (55%), whereas in this
study 70% of TB due to M. bovis occurred in French-born
patients (4 of the patients had been born abroad).
Therefore, human disease due to M . bovis, in contrast with
that due to M. tuberculosis, appears to be predominantly
indigenous in France, according to our study. However, we
must note that human M. bovis infection varies throughout
the world, even in industrialized countries, as reported in
MMWR in 2005 when patients infected in New York were
young persons born in Mexico or children of Mexican-
born parents (16). Finally, we should note that French
patients with M. bovis infections, in contrast to patients
born abroad, were usually >50 years of age and sought
treatment for a torpid infection. Measures to reduce bovine
TB and the human transmission of M. bovis began in the
1950s. The disease was due to the reactivation of a past
infection that had been acquired before milk pasteurization
rather than a primary infection. Few cases have been
reported in French-born children, which is in accordance
with the effectiveness of preventive measures and their
long-term effect. We cannot tell whether this is an emerg-
ing or a reemerging disease, but M. bovis is clearly still
responsible for human TB. Global monitoring is required
to confirm the progress of the disease and perhaps to
explain why it is (re)emerging. In summary, we found the
combination of spoligotyping and MIRU-VNTR to be a
useful tool for identifying M. bovis infections and for
determining whether patients were infected with the same
strain. In our population of patients in Lyon, France, we
did not detect any clonal epidemiologic features for M.
bovis disease.
Dr Mignard is a clinical scientist in the Department of
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